Araceli Biosciences Inc. — SEC Form D Filing

Araceli Biosciences Inc. filed an SEC Form D on November 3, 2026, reporting $2.53M raised in Other Technology.

Form D filing details

Filing
SEC Form D
Filing date
November 3, 2026
Amount reported
$2.53M
Round stage
Seed stage, as indicated by a $2.5M debt financing round used to scale early platform commercialization and customer deployment.
Industry
Other Technology
Website
https://aracelibio.com

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional biological imaging tools process high-density microplates slowly, creating a severe data bottleneck for high-throughput drug discovery.

Solution

Araceli Biosciences builds high-speed cellular imaging hardware and real-time AI analysis software that can image a 1,536-well plate in under four minutes.

Why now

The rapid convergence of automated robotics and AI-driven biological modeling requires unprecedented volumes of high-quality cellular data generated at extreme speed.

Source: SEC EDGAR Form D filing